<DOC>
	<DOCNO>NCT01927120</DOCNO>
	<brief_summary>IL-2 add-back post allogeneic hematopoietic stem cell transplant ( HSCT ) , combine Sirolimus ( SIR ) , Tacrolimus ( TAC ) optimize Treg reconstitution prevent graft versus host disease ( GVHD ) .</brief_summary>
	<brief_title>In Vivo Treg Expansion Graft-Versus-Host Disease Prophylaxis</brief_title>
	<detailed_description>1 ) Determine GVHD prophylaxis regimen IL-2/SIR/TAC enhances vivo Treg differentiation growth ; 2 ) Study safety effect IL-2/SIR/TAC incidence acute chronic GVHD ; 3 ) Evaluate influence dual IL-2 supplementation mammalian target rapamycin ( mTOR ) inhibition T cell-specific signaling pathway polarization emerge T helper cell .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients must available 8/8 human leukocyte antigen ( HLA ) A , B , C , DRB1 matchedrelated unrelated donor allogeneic hematopoietic peripheral blood stem cell graft . Acute myeloid leukemia , myelodysplasia , acute lymphoblastic leukemia , chronic myeloid leukemia , myeloproliferative neoplasm require match allogeneic HSCT . Acute Leukemia ( AML ALL ) must complete remission define : &lt; 5 % marrow blast morphologic evidence leukemia , peripheral blast , marrow &gt; 20 % cellular , peripheral absolute neutrophil count &gt; 1000/µL ( platelet recovery require ) . Myelodysplasia ( MDS ) chronic myeloid leukemia ( CML ) : Must &lt; 5 % marrow blast . Myeloproliferative neoplasm ( MPN ) : Must &lt; 5 % peripheral / marrow blast . Adequate vital organ function : 1 . Left ventricular ejection fraction ( LVEF ) ≥ 45 % multi gate acquisition ( MUGA ) scan ECHO 2 . Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) , adjust diffuse lung capacity oxygenation ( DLCO ) ≥ 50 % predict value pulmonary function test 3 . Transaminases ( AST , ALT ) &lt; 2 time upper limit normal value 4 . Creatinine clearance ≥ 50 cc/min . Performance status : Karnofsky Performance Status Score ≥ 80 % Donor eligibility : Eligible donor include healthy sibling , relative unrelated donor match patient HLAA , B , C , DRB1 high resolution type . Active infection control appropriate antimicrobial therapy History HIV , hepatitis B , hepatitis C infection Antithymocyte globulin , alemtuzumab , bortezomib , cyclophosphamide administer within 14 day plan receive HCT condition part GVHD prophylaxis 14 day HCT . Hypersensitivity recombinant human IL2 Chronic lymphocytic leukemia , Hodgkin lymphoma , nonhodgkin lymphoma exclude malignancy may express IL2 receptor pose potential growth signal present disease . Sorror 's comorbidity factor total score &gt; 4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GVHD</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Hematopoietic Cell Transplant</keyword>
</DOC>